Drug Trial Radar · NCT01363648
The Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no Dementia
Last checked: Nov 20, 2026Latest source record: Oct 14, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
222
Actual
Start
Nov 2010
Primary completion
Mar 2013
Study completion Mar 2013
Sponsor
- Lead sponsor
- Seoul National University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 1, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 25 years, up to 84 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To date, there are no approved treatments for vascular cognitive impairment (VCI) and the main therapeutic efforts are aimed at controlling vascular risk factors for countering VCI development or progression. Several studies have reported cholinergic deficits in brain and cerebrospinal fluid of patients with VCI. The effect of choline alphoscerate in clinical studies of Alzheimer's disease and VCI improved memory and attention impairments. The purpose of our study is to determine effectiveness of choline alphoscerate vs placebo in improving cognition in post-stroke patients with VCI-non dementia (VCI-ND).
Conditions
- Cognitive Impairment
- Stroke
Interventions
choline alfoscerateDrug
Participants were randomly assigned to twice-daily doses of 400mg choline alphoscerate (alpha-glyceryl phosphoryl choline, Gliatilin®)
placebo (for choline alphoscerate)Drug
Pill manufactured to mimic choline alfoscerate 400mg tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- the change of K-TMT-e A of K-VCIHS-NP in the choline alfoscerate vs the placebo groups.Time frame: 12 weeks after taking drugs
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Bundang
Seongnam, Gyeoinggido, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.